BR0215454A - Terapia combinada contra tumores, comprendendo derivados de acriloil-distamicina substituìdos e inibidores de proteìna cinase (serina/treonina cinase) - Google Patents
Terapia combinada contra tumores, comprendendo derivados de acriloil-distamicina substituìdos e inibidores de proteìna cinase (serina/treonina cinase)Info
- Publication number
- BR0215454A BR0215454A BR0215454-4A BR0215454A BR0215454A BR 0215454 A BR0215454 A BR 0215454A BR 0215454 A BR0215454 A BR 0215454A BR 0215454 A BR0215454 A BR 0215454A
- Authority
- BR
- Brazil
- Prior art keywords
- serine
- tumor therapy
- distamycin derivatives
- derivatives
- kinase inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- -1 acryloyl distamycin derivatives Chemical class 0.000 title abstract 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 2
- 239000003909 protein kinase inhibitor Chemical class 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 title 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical class CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000012268 protein inhibitor Substances 0.000 abstract 1
- 229940121649 protein inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"TERAPIA COMBINADA CONTRA TUMORES, COMPRENDENDO DERIVADOS DE ACRILOIL-DISTAMICINA SUBSTITUìDOS E INIBIDORES DE PROTEìNA CINASE (SERINA/TREONINA CINASE)". A presente invenção refere-se ao uso combinado de derivados de acriloil-distamicina, particularmente os derivados <244>-bromo- e <244>-cloroacriloil-distamicina da fórmula (I), como enunciado no relatório descritivo, e um inibidor de proteína cinase (serina/treonina e tirosina cinases), no tratamento de tumores. Além disso, refere-se ao uso das ditas combinações no tratamento ou prevenção de metástase ou no tratamento de tumores pela inibição de angiogênese.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02075052 | 2002-01-02 | ||
| PCT/EP2002/013092 WO2003055522A1 (en) | 2002-01-02 | 2002-12-18 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0215454A true BR0215454A (pt) | 2004-11-23 |
Family
ID=8185508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0215454-4A BR0215454A (pt) | 2002-01-02 | 2002-12-18 | Terapia combinada contra tumores, comprendendo derivados de acriloil-distamicina substituìdos e inibidores de proteìna cinase (serina/treonina cinase) |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20060084612A1 (pt) |
| EP (1) | EP1461083B1 (pt) |
| JP (1) | JP2005516025A (pt) |
| KR (1) | KR20040078118A (pt) |
| CN (1) | CN1617744A (pt) |
| AT (1) | ATE321572T1 (pt) |
| AU (1) | AU2002352090B8 (pt) |
| BR (1) | BR0215454A (pt) |
| CA (1) | CA2472008C (pt) |
| CY (1) | CY1105269T1 (pt) |
| DE (1) | DE60210329T2 (pt) |
| DK (1) | DK1461083T3 (pt) |
| ES (1) | ES2263835T3 (pt) |
| HU (1) | HUP0402639A3 (pt) |
| IL (2) | IL162820A0 (pt) |
| MX (1) | MXPA04006543A (pt) |
| NO (1) | NO20043217L (pt) |
| NZ (1) | NZ533854A (pt) |
| PL (1) | PL371179A1 (pt) |
| PT (1) | PT1461083E (pt) |
| RU (1) | RU2328306C2 (pt) |
| SI (1) | SI1461083T1 (pt) |
| WO (1) | WO2003055522A1 (pt) |
| ZA (1) | ZA200405290B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1545553T3 (da) * | 2002-07-30 | 2011-09-12 | Aeterna Zentaris Gmbh | Anvendelse af alkylphosphocholiner i kombination med antitumormedikamenter |
| US8383605B2 (en) | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
| CN101141955A (zh) * | 2005-04-08 | 2008-03-12 | 内尔维阿诺医学科学有限公司 | 包含被取代的丙烯酰基偏端霉素衍生物以及抑制生长因子或其受体的抗体的抗肿瘤组合 |
| US8383607B2 (en) | 2010-03-31 | 2013-02-26 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274576B1 (en) * | 1995-06-27 | 2001-08-14 | The Henry Jackson Foundation For The Advancement Of Military Medicine | Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
| GB9615692D0 (en) * | 1996-07-25 | 1996-09-04 | Pharmacia Spa | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents |
| GB0015447D0 (en) * | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents |
| GB0015444D0 (en) * | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors |
-
2002
- 2002-12-18 AU AU2002352090A patent/AU2002352090B8/en not_active Ceased
- 2002-12-18 MX MXPA04006543A patent/MXPA04006543A/es active IP Right Grant
- 2002-12-18 ES ES02787763T patent/ES2263835T3/es not_active Expired - Lifetime
- 2002-12-18 KR KR10-2004-7010472A patent/KR20040078118A/ko not_active Application Discontinuation
- 2002-12-18 AT AT02787763T patent/ATE321572T1/de active
- 2002-12-18 US US10/500,606 patent/US20060084612A1/en not_active Abandoned
- 2002-12-18 CA CA002472008A patent/CA2472008C/en not_active Expired - Fee Related
- 2002-12-18 RU RU2004123641/15A patent/RU2328306C2/ru not_active IP Right Cessation
- 2002-12-18 HU HU0402639A patent/HUP0402639A3/hu unknown
- 2002-12-18 BR BR0215454-4A patent/BR0215454A/pt not_active IP Right Cessation
- 2002-12-18 PT PT02787763T patent/PT1461083E/pt unknown
- 2002-12-18 JP JP2003556098A patent/JP2005516025A/ja active Pending
- 2002-12-18 NZ NZ533854A patent/NZ533854A/en not_active IP Right Cessation
- 2002-12-18 EP EP02787763A patent/EP1461083B1/en not_active Expired - Lifetime
- 2002-12-18 IL IL16282002A patent/IL162820A0/xx unknown
- 2002-12-18 PL PL02371179A patent/PL371179A1/xx not_active Application Discontinuation
- 2002-12-18 WO PCT/EP2002/013092 patent/WO2003055522A1/en active IP Right Grant
- 2002-12-18 SI SI200230335T patent/SI1461083T1/sl unknown
- 2002-12-18 DK DK02787763T patent/DK1461083T3/da active
- 2002-12-18 CN CNA028276744A patent/CN1617744A/zh active Pending
- 2002-12-18 DE DE60210329T patent/DE60210329T2/de not_active Expired - Lifetime
-
2004
- 2004-07-01 IL IL162820A patent/IL162820A/en not_active IP Right Cessation
- 2004-07-02 ZA ZA200405290A patent/ZA200405290B/xx unknown
- 2004-07-29 NO NO20043217A patent/NO20043217L/no not_active Application Discontinuation
-
2006
- 2006-06-05 CY CY20061100717T patent/CY1105269T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL162820A0 (en) | 2005-11-20 |
| DK1461083T3 (da) | 2006-07-10 |
| WO2003055522A1 (en) | 2003-07-10 |
| SI1461083T1 (sl) | 2006-08-31 |
| CY1105269T1 (el) | 2010-03-03 |
| NZ533854A (en) | 2007-05-31 |
| KR20040078118A (ko) | 2004-09-08 |
| IL162820A (en) | 2010-04-15 |
| AU2002352090A1 (en) | 2003-07-15 |
| AU2002352090B2 (en) | 2008-05-15 |
| PL371179A1 (en) | 2005-06-13 |
| DE60210329T2 (de) | 2006-11-30 |
| EP1461083A1 (en) | 2004-09-29 |
| ATE321572T1 (de) | 2006-04-15 |
| CA2472008A1 (en) | 2003-07-10 |
| CN1617744A (zh) | 2005-05-18 |
| RU2004123641A (ru) | 2005-06-10 |
| ES2263835T3 (es) | 2006-12-16 |
| HUP0402639A2 (hu) | 2005-04-28 |
| RU2328306C2 (ru) | 2008-07-10 |
| AU2002352090B8 (en) | 2008-06-19 |
| US20060084612A1 (en) | 2006-04-20 |
| NO20043217L (no) | 2004-07-30 |
| EP1461083B1 (en) | 2006-03-29 |
| MXPA04006543A (es) | 2004-10-04 |
| ZA200405290B (en) | 2005-06-17 |
| DE60210329D1 (de) | 2006-05-18 |
| JP2005516025A (ja) | 2005-06-02 |
| CA2472008C (en) | 2009-07-28 |
| PT1461083E (pt) | 2006-08-31 |
| HUP0402639A3 (en) | 2012-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| BR0208373A (pt) | Inibidores da tirosina cinase | |
| YU61402A (sh) | Pirol substituisani 2 indolinon protein kinazni inhibitori | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| IL191832A (en) | Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors | |
| ATE297394T1 (de) | Jun kinase inhibitoren | |
| ATE300529T1 (de) | Imidazolderivate als raf-kinase-inhibitoren | |
| MY126132A (en) | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | |
| CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| ATE343575T1 (de) | Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz | |
| MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. | |
| BR0215454A (pt) | Terapia combinada contra tumores, comprendendo derivados de acriloil-distamicina substituìdos e inibidores de proteìna cinase (serina/treonina cinase) | |
| GB0015444D0 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors | |
| WO2002074756A3 (de) | Urokinase-inhibitoren | |
| MXPA02012209A (es) | Terapia combinada contra tumores que comprende derivados de bistamicina acriloilo substituida y agentes de alquilacion. | |
| MXPA02012165A (es) | Terapia combinada contra tumores que comprende derivados de acriloil-distamicina sustituida, taxanos y/o antimetabolitos. | |
| BR0308976A (pt) | Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia | |
| SE0302824D0 (sv) | New use | |
| DE50301954D1 (de) | Liposomale formulierungen von phenylalanin-derivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: PFIZER ITALIA S.R.L. (IT) Free format text: TRANSFERIDO POR FUSAO DE: PHARMACIA ITALIA SPA |
|
| B25A | Requested transfer of rights approved |
Owner name: NERVIANO MEDICAL SCIENCE S.R.L. (IT) Free format text: TRANSFERIDO DE: PFIZER ITALIA S.R.L. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES. |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |